SEATTLE, Jan. 4, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that the company will be presenting at the 9th Annual Biotech Showcase Conference. Robert W. Overell, Ph.D., president and chief executive officer, will provide an overview of the company and its development stage programs on Tuesday, January 10, 2017 at 3:30 p.m. PST (6:30 p.m. EST). The conference will be held from January 9-11, 2017 in San Francisco.
A live audio webcast and replay will be available on the investor relations section of PhaseRx's corporate website at www.phaserx.com and will be archived following the presentation for 90 days. Please connect to PhaseRx's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
PhaseRx is a biopharmaceutical company dedicated to developing mRNA products for the treatment of children with inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of twelve and are characterized by the body's inability to remove ammonia from the blood with potentially devastating consequences for patients. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology™ platform. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.
Director of Investor Relations
Corporate Communications Contact:
Senior Vice President
Robert H. Uhl
Westwicke Partners, LLC
SOURCE PhaseRx, Inc.